Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib + Erlotinib in EGFR Mutant NSCLC
NCT02342353Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- May 2015
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pacritinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose and Objective Response Rate up to 5 years. Started May 2015; status: terminated.
02
Drugs
pacritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02342353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342353.